PPARG and inflammatory bowel disease: Through phenotypic screening, the peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist pioglitazone (Actos), which was originally approved for use as a diabetic therapeutic, has been shown to have therapeutic use in treating inflammatory bowel disease (Wang and DuBois, 2010).